Sera Prognostics Announces Financial Performance for Q3 2025 with Expansion Initiatives

Overview of Sera Prognostics Q3 Performance

Sera Prognostics Inc., known as The Pregnancy Company® and traded on Nasdaq under the ticker SERA, announced its financial results for the third quarter of 2025 on November 13. The company is dedicated to enhancing maternal and neonatal health by providing innovative pregnancy biomarker information to healthcare professionals and patients.

Key Highlights

In the recent quarter, Sera has made significant strides in their initiatives with payers. They launched an inaugural pilot program in Nevada aimed at enrolling Medicaid patients, and are engaging with multiple payers across thirteen states, marking a considerable market opportunity. Sera is also in discussions with various organizations that operate on both regional and national levels across multiple business lines. This early engagement indicates that the company is well-positioned to foster adoption in targeted states and beyond.

Sera is also on track to release full findings from its critical study, the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal Outcomes (PRIME), later this year. This announcement will be closely followed by additional insights regarding health economics, sub-population analyses, and the expected cost-saving benefits related to their PreTRM Test within Medicaid.

Continuing Medical Engagement

The company has sustained its interaction with the medical community, recently presenting PRIME data at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe conference. Dr. Brian Iriye also discussed biomarker-guided care at the inaugural Renaissance Conference. Sera has fortified its leadership team with new appointments, including Dr. Tiffany Inglis as Chief Medical Officer, who boasts over a decade of clinical experience as an OBGYN, and Marisol Urbano as Head of Commercial Operations, bringing extensive diagnostics experience.

"The groundwork we've laid is starting to yield commercial traction; our PRIME study results are driving significant engagement with managed Medicaid and other key stakeholders," stated Zhenya Lindgardt, President and CEO. The company aims to lock down broad payer coverage, which is crucial for unlocking value at a larger scale, particularly with Medicaid responsible for a substantial percentage of U.S. births.

Financial Results Overview

In terms of financial performance for Q3 2025, Sera reported revenue of $16,000, a drop from the previous year’s $29,000. The company's deferred revenue rose by $100,000 due to prepayment from the Nevada Medicaid pilot, marking a positive trend. The total operating expenses stood at $9.0 million—a slight increase compared to the previous year.

Research and development expenses were $3.3 million, which represents a decrease, reflecting the completion of the PRIME study and the shift toward commercialization. Conversely, selling, general, and administrative expenses rose to $5.7 million as Sera invested in strategic activities to increase market awareness.

Sera's net loss for the quarter was $7.8 million, slightly improved from the $7.9 million loss endured in the same quarter last year. As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled approximately $102.4 million, providing a solid foundation to cover substantial adoption and commercial milestones up to 2028.

Future Outlook and Conference Call

Sera Prognostics will host a conference call today at 5:00 p.m. Eastern Time to delve into operational highlights and financial results. Interested parties can participate via a dial-in number or through a live audio webcast available on the company's website.

About Sera Prognostics, Inc.

Sera Prognostics is committed to improving the lives of women and their children through precision pregnancy care, hoping to provide vital early pregnancy information that enhances health outcomes. Their innovative PreTRM® Test is the only broadly validated blood-based biomarker test that predicts the risk of preterm birth, allowing healthcare providers to make individualized decisions for patients.

Conclusion

Sera Prognostics continues on its path toward significant enhancements in maternal and neonatal healthcare. With promising financial updates and strategic expansion into Medicaid programs, the company is strategically poised to make a substantial impact in maternal healthcare, drive revenue growth, and subsequently, boost shareholder value.